- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00674349
Screening of Biomarkers on Endometrial Cancers
Screening and Identification of Novel Diagnostic and Prognostic Biomarkers on Endometrial Cancers
Ovarian cancer is the first mortality rate of gynecologic malignancies. The incidence of ovarian cancer increased in recent 10 years and it has become the ninth cause of malignancies in the women in Taiwan. From the above-mentioned data, ovarian cancer indeed is a disease that should be respected, however, there were only few of research work focusing on it in Taiwan. Despite the widespread use of aggressive cytoreductive surgery and the introduction of chemotherapy regimens, the overall survival has changed little over the last two decades. The basic problem in treating epithelial ovarian cancer is that once it has spread beyond the ovary, it is exceedingly difficult to control and ultimately to cure. More than 70% of ovarian cancer patients were advanced stage when diagnosed. To study the mechanisms of carcinogenesis, progression, and metastasis of ovarian cancer will help us understand this disease and develop new treatment strategies for ovarian cancer in the future.
We have established an ascitogenic itnraperitoneal tumor cell line-WF3 in the mouse model in our previous two-year project of NSC grant (grant number (NSC90-2314-B-002-457 and NSC91-2341-B-002-315). Our group found that, mesothelin, this molecule is highly related with the carcinogenesis, tumor progression and tumor metastasis in our animal model and human cancer tissues. To further evaluate the role of mesothelin in ovarian cancer and elucidate the potential of mesothelin as a target antigen for immunotherapy,
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- National Taiwan University Hospital
-
Contact:
- WEN-FANG CHENG, ASSOCIATE PROFESSOR
- Phone Number: 886-2-23123456
- Email: wenfangcheng@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with endometrial cancers who undergo hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and appendectomy will be enrolled and the clinical data will be obtained from our hospital. All of the patients received four to six courses of adjuvant platinum-containing chemotherapy.Histologic grading was according to International Union against Cancer criteria (28). The stage of disease was classified according to the International Federation of Gynecology and Obstetrics (FIGO, 1987). Pelvic and paraaortic lymph node samplings will be performed, if the disease will be confined to within the ovary or will be without a ruptured capsule. The histopathologic data, including histologic type and histologic grade, will be evaluated by a certified pathologist. The maximal diameter of the residual tumor after surgery will be also recorded. All patients will be followed up at 3-month intervals.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
overall survival
Time Frame: from disease diagnosis to death
|
from disease diagnosis to death
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 200706001R
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Cancers
-
CHU de ReimsUnknownEndometrial Hyperplasia and Endometrial CancersFrance
-
National Cancer Institute (NCI)Mayo ClinicCompletedEndometrial Cancer | Gynecological CancersUnited States
-
Five Prime Therapeutics, Inc.Worldwide Clinical TrialsWithdrawnEndometrial Cancers With FGFR2 Mutations
-
Duke UniversityCompletedHead and Neck Cancers | Lung and Esophagus Cancers | Anal, Cervix, Vulvar, Vaginal, and Endometrium CancersUnited States
-
Agenus Inc.CompletedAdvanced Solid Cancers | Advanced Solid Cancers Refractory to PD-1United States
-
NucMito Pharmaceuticals Co. Ltd.Recruiting
-
Ann & Robert H Lurie Children's Hospital of ChicagoRecruiting
-
Institute of Oncology LjubljanaRecruiting
-
M.D. Anderson Cancer CenterEuropean CommissionCompletedAdvanced CancersUnited States, Spain, France, Israel
-
Aeglea BiotherapeuticsCompletedAdvanced CancersUnited States
Clinical Trials on surgery
-
University of AarhusCompletedAcute Post Operative Pain | Chronic Postsurgical PainDenmark
-
International Study Group on Minimally Invasive...Fondazione CARIT; LOGIX S.r.l.Unknown
-
Peking Union Medical College HospitalCompletedPancreatic Neuroendocrine TumorsChina
-
Hospital Central de la Defensa Gómez UllaClinica Universidad de Navarra, Universidad de NavarraEnrolling by invitationRectal Cancer | PROM | Functional Bowel DisorderSpain
-
Sunnybrook Health Sciences CentreMcMaster University; Unity Health Toronto; University of Toronto; University of... and other collaboratorsCompleted
-
The Second Hospital of Shandong UniversityRecruitingLung Diseases | SurgeryChina
-
Federal University of São PauloUnknownObesity | LymphedemaBrazil
-
Shanghai Zhongshan HospitalUnknownCarcinoma, Pancreatic Ductal | Circulating Tumor CellsChina
-
NHS GrampianBarts & The London NHS Trust; Queen Mary University of London; University of...RecruitingOvarian CancerUnited Kingdom
-
The Christie NHS Foundation TrustUniversity of ManchesterRecruitingQuality of Life | Lung NeoplasmsUnited Kingdom